India, April 16 -- Acurx Pharmaceuticals, Inc. (ACXP), a late-stage biopharmaceutical company announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 0.825 million shares at a purchase price of $3.03 per share in a registered direct offering. The aggregate gross proceeds are expected to be approximately $2.5 million.
In parallel, in a concurrent private placement, the firm will issue unregistered short-term warrants to purchase up to 1.65 million shares, with an exercise price of $2.78 per share, exercisable immediately and expiring twenty-four months following the effective date of the registration.
The potential additional gross proceeds from the short-term warrants, if fully-exercised on a...